Ticlopidine is an oral antiplatelet agent frequently utilized in the treatment of cerebrovascular disease. It is rarely associated with severe bone marrow suppression. A case of an elderly woman is reported who developed febrile agranulocytosis two months after commencing ticlopidine but who had a favorable outcome after cessation of that drug and treatment with granulocyte colony-stimulating factor (G-CSF). All patients should have regular monitoring of their blood counts during therapy with ticlopidine.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/000331970005100707 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Characterization of ticlopidine-induced developmental and teratogenic defects in Xenopus embryos and human endothelial cells.
Chem Biol Interact
October 2015
ABRC, CMRI, School of Life Sciences, BK21 Plus KNU Creative BioResearch Group, Kyungpook National University, Daegu, 702-701, South Korea. Electronic address:
Ticlopidine is an anti-platelet drug that inhibits platelet aggregation via the functional alteration of platelet membranes. However, the mechanism underlying the adverse developmental effects of ticlopidine has not been clearly demonstrated. In this study, we evaluated the developmental toxicity and teratogenicity of ticlopidine on Xenopus laevis embryos and in human umbilical vein endothelial cells (HUVECs) using a frog embryo teratogenesis assay-Xenopus (FETAX) and blood and lymph vessel formation assays.
View Article and Find Full Text PDF[A case of ticlopidine induced acute cholestatic hepatitis and pure red cell aplasia].
Korean J Hepatol
March 2008
Korea University Medical College Guro Hospital, Department of Internal Medicine, Seoul, Korea.
Ticlopidine inhibits platelet aggregation and provides beneficial secondary prevention of cerebrovascular and coronary artery disease. Frequently reported adverse effects of ticlopidine include diarrhea, nausea, and rash. However, to our knowledge, there are only a few published reports of the simultaneous occurrence of cholestatic hepatitis and pure red cell aplasia.
View Article and Find Full Text PDFSevere ticlopidine-induced cholestatic syndrome.
Blood Purif
March 2008
UO Nefrologia, Dialisi e Ipertensione Malpighi, Policlinico S. Orsola-Malpighi, Bologna, Italy.
A patient with chronic renal insufficiency undergoing dialysis treatment presented with a clinical picture of acute intrahepatic cholestasis and alterations in liver function indices. Liver biopsy showed a histological picture of hepatitis with cholestatic signs. A causal correlation with the recent administration of ticlopidine was hypothesized, which led to the drug being discontinued.
View Article and Find Full Text PDFTiclopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study.
Pharmacogenomics J
February 2008
Product Lifecycle Management Department, Daiichi Pharmaceutical Co. Ltd., 1-8 Nihonbashi-Koamicho, Chuo-ku, Tokyo, Japan.
Genetic risk factors for ticlopidine-induced hepatotoxicity were determined in 22 Japanese patients with ticlopidine-induced hepatotoxicity and 85 Japanese patients who tolerated ticlopidine therapy without experiencing adverse reactions. There was a significant correlation between ticlopidine-induced hepatotoxicity and five human leukocyte antigen (HLA) alleles: HLA-A*3303, HLA-B*4403, HLA-Cw*1403, HLA-DRB1*1302 and HLA-DQB1*0604 (corrected probability (P)-value (Pc)<0.01).
View Article and Find Full Text PDFThrombotic thrombocytopenic purpura.
J Thromb Haemost
August 2005
Department of Hematology and Central Hematology Laboratory, Inselspital, University Hospital, Bern, Switzerland.
This overview summarizes the history of thrombotic thrombocytopenic purpura (TTP) from its initial recognition in 1924 as a most often fatal disease to the discovery in 1997 of ADAMTS-13 deficiency as a major risk factor for acute disease manifestation. The cloning of the metalloprotease, ADAMTS-13, an essential regulator of the extremely adhesive unusually large von Willebrand factor (VWF) multimers secreted by endothelial cells, as well as ADAMTS-13 structure and function are reviewed. The complex, initially devised assays for ADAMTS-13 activity and the possible limitations of static in vitro assays are described.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!